Evidence map›Paper›PMID 24591201›Full record

Trial reportBlood2014

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Ian W Flinn, Richard van der Jagt, Brad S Kahl, Peter Wood, Tim E Hawkins, David Macdonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig and 7 more

3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 296 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
296citing papers in PubMed, 7 pooled it
39.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00877006 phase3completednot on this map

An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

TypeinterventionalSponsorTeva Branded Pharmaceutical Products R&D, Inc.Ran2009 to 2012Enrolled447ConditionsNon-Hodgkin's Lymphoma, Mantle Cell LymphomaArmsbendamustine, rituximab, vincristine, prednisone, cyclophosphamide
NCT02278796 phase2completednot on this mapstarted 2015, after this paper: background citation

A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2015 to 2020Enrolled108ConditionsLymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-CellArmsBeEAM, BEAM
NCT04943302 phase2withdrawnnot on this mapstarted 2022, after this paper: background citation

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

TypeinterventionalSponsorTufts Medical CenterRan2022 to 2026Enrolled0ConditionsAmyloidosis, Light Chain (AL) AmyloidosisArmsBendamustine Hydrochloride, Isatuximab
3 · Its place in the literature

Who cites it

296 citing papers in PubMed, 7 syntheses or guidelines pooled it, 626 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Lenalidomide plus rituximab (RBritish journal of haematology · 2019
    Trial
  19. Trial
  20. Article

236 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 4 countries.

Ian W FlinnSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;
Richard van der Jagt
Brad S Kahl
Peter Wood
Tim E Hawkins
David Macdonald
Mark Hertzberg
Yiu-Lam Kwan
David Simpson
Michael Craig
Kathryn Kolibaba
Samar Issa
Regina Clementi
Doreen M Hallman
Mihaela Munteanu
Ling Chen
John M Burke
Teva Pharmaceuticals (United States) · USAuckland City Hospital · NZCompass Oncology · USConcord Repatriation General Hospital · AUDalhousie University · CAMcKesson (United States) · USMiddlemore Hospital · NZNorth Shore Hospital · NZPrincess Alexandra Hospital · AUSarah Cannon · USUniversity of Ottawa · CAUniversity of Wisconsin Carbone Cancer Center · USWestmead Hospital · AUWest Virginia University · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab plus cyclophosphamide, vincristine, and prednisone [R-CVP]) for treatment-naive patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma. Investigators preassigned the standard treatment regimen they considered most appropriate for each patient; patients were randomized to receive BR (n = 224) or standard therapy (R-CHOP/R-CVP, n = 223) for 6 cycles; 2 additional cycles were permitted at investigator discretion. Response was assessed by a blinded independent review committee. BR was noninferior to R-CHOP/R-CVP, as assessed by the primary end point of complete response rate (31% vs 25%, respectively; P = .0225 for NI [0.88 margin]). The overall response rates for BR and R-CHOP/R-CVP were 97% and 91%, respectively (P = .0102). Incidences of vomiting and drug-hypersensitivity reactions were significantly higher in patients treated with BR (P < .05), and incidences of peripheral neuropathy/paresthesia and alopecia were significantly higher in patients treated with standard-therapy regimens (P < .05). These data indicate BR is noninferior to standard therapy with regard to clinical response with an acceptable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT00877006.

Indexed as

AdultAgedAged, 80 and overAlopeciaAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideCyclophosphamideDoxorubicinDrug Administration ScheduleFatigueFemaleHumansLymphoma, Mantle-CellLymphoma, Non-HodgkinMaleAntibodies, Monoclonal, Murine-DerivedBendamustine HydrochlorideCyclophosphamideDoxorubicinNitrogen Mustard CompoundsPrednisoneRituximabVincristine

Identifiers

PMID24591201
PMCPMC4260975
OpenAlexW2085346499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.